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The noncatalytic domain of protein-tyrosine phospha-
tase (PTP)-PEST contains a binding site for the focal
adhesion-associated protein paxillin. This binding site
has been narrowed to a 52-residue sequence that is com-
posed of two nonoverlapping, weak paxillin binding
sites. The PTP-PEST binding site on paxillin has been
mapped to the two carboxyl-terminal LIM (lin11, isl-1,
and mec-3) domains. Transient expression of PTP-PEST
reduced tyrosine phosphorylation of p130cas, as antici-
pated. A PTP-PEST mutant defective for binding p130cas
does not cause a reduction in its tyrosine phosphoryla-
tion in vivo. Expression of PTP-PEST also caused a re-
duction of phosphotyrosine on paxillin. Expression of
mutants of PTP-PEST with deletions in the paxillin-
binding site did not associate with paxillin in vivo and
failed to cause a reduction in the phosphotyrosine con-
tent of paxillin. These results demonstrate that paxil-
lin can serve as a PTP-PEST substrate in vivo and
support the model that a noncatalytic domain interac-
tion recruits paxillin to PTP-PEST to facilitate its
dephosphorylation.
A major mechanism of signal transduction utilized by the
integrins is the activation of PTKs1 (1). One prominent PTK in
this signaling pathway is FAK. FAK has been implicated in the
regulation of a number of important biological functions, in-
cluding cell spreading, cell motility, cell survival, and cell
growth (2–8). One feature of FAK that is essential for signaling
is its autophosphorylation and association with Src family
PTKs. Several focal adhesion-associated, FAK-binding proteins
also become tyrosine-phosphorylated in response to activation
of integrin signaling pathways including paxillin and p130cas.
Tyrosine phosphorylation of paxillin may function in control-
ling the rate of cell spreading (9). Tyrosine phosphorylation of
p130cas has been implicated in controlling cell motility (10, 11).
The interactions of paxillin and p130cas with SH2 domain con-
taining signaling molecules is regulated by tyrosine phospho-
rylation, and assembly of the p130cas/crk complex appears to be
important in regulating cell motility (11).
Although tyrosine phosphorylation of focal adhesion-associ-
ated proteins has been intensively investigated, the dephospho-
rylation of these proteins has not been extensively studied until
recently. PTPs function to dephosphorylate tyrosine-phospho-
rylated substrates and a number of candidate PTPs that may
regulate signaling through focal adhesion-associated proteins
have recently been identified. In MCF7 cells, a fraction of the
transmembrane PTP leukocyte common antigen-related pro-
tein was localized in focal adhesions, although there is no
evidence implicating leukocyte common antigen-related pro-
tein in the regulation of tyrosine phosphorylation of focal ad-
hesion-associated proteins (12). There is biochemical evidence
suggesting that two focal adhesion-associated proteins, FAK
and p130cas, are substrates for PTEN/MMAC1 (phosphatase
and tensin homolog deleted on chromosome 10/mutated in mul-
tiple advanced cancers 1) (13, 14). Further, perturbation of
PTEN expression levels alters the ability of cells to spread and
migrate, biological functions that FAK and p130cas are believed
to control (13). Similarly, PTP1B has been implicated in regu-
lating the phosphotyrosine content of FAK, paxillin, and
p130cas and in controlling the rate of cell spreading and migra-
tion (15–17). In addition, PTP1B can associate with p130cas via
an SH3 domain mediated interaction and may sometimes lo-
calize to focal adhesions (16, 17). The SH2 domain containing
PTP, SHP2, can be coimmunoprecipitated with FAK (18). In
fibroblasts lacking functional SHP2, the phosphotyrosine con-
tent of FAK and paxillin is perturbed and the cells exhibit
retarded spreading on fibronectin and reduced motility (18, 19).
One other candidate PTP for regulation of focal adhesion-
associated proteins is PTP-PEST. This PTP was first impli-
cated in this function when p130cas was identified as a PTP-
PEST substrate using a substrate trapping approach (20). In
addition, there are binding sites in the noncatalytic domain of
PTP-PEST for both the SH3 domain of p130cas and for paxillin
(21, 22). Overexpression of PTP-PEST in Rat 1 fibroblasts
reduces tyrosine phosphorylation of p130cas, but not tyrosine
phosphorylation of FAK or paxillin, and retards cell motility
(23). Conversely, PTP-PEST2/2 fibroblasts exhibit elevated
levels of tyrosine phosphorylation of p130cas (24). These cells
also exhibit dramatic elevation in the phosphotyrosine content
of both FAK and paxillin (24). The PTP-PEST2/2 cells spread
more rapidly than wild type cells but show reduced motility
(24).
In this report, we further characterize the interaction of
PTP-PEST with paxillin. The PTP-PEST binding site on pax-
illin is localized to the two carboxyl-terminal LIM domains. The
paxillin-binding site on PTP-PEST is shown to reside close to,
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but is independent of, the p130cas-binding site. Although pax-
illin does not associate with substrate trapping constructs of
PTP-PEST, expression of PTP-PEST in 293 cells results in a
reduction in the level of tyrosine phosphorylation of endoge-
nous paxillin. Using mutants of PTP-PEST, we demonstrate
that the interaction of p130cas and paxillin with the noncata-
lytic domain of PTP-PEST is required for their dephosphoryl-
ation in vivo.
MATERIALS AND METHODS
Cells—Chicken embryo (CE) cells were prepared and cultured as
described previously (25). 293 cells were maintained in Dulbecco’s mod-
ified Eagle’s medium/Ham’s F-12 medium supplemented with 10% fetal
bovine serum and COS cells in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum. Cells were transfected
using LipofectAMINE (Life Technologies Inc.) following the manufac-
turer’s recommended protocol.
Molecular Biology—For expression as GST fusion proteins, frag-
ments of PTP-PEST were amplified by PCR using the PTP-PEST cDNA
as template. Primers were designed to create a 59 BamHI site and a 39
EcoRI site, and the fragments were inserted between the BamHI and
EcoRI sites of the multiple cloning site of pGEX-2TK (Amersham Phar-
macia Biotech), in-frame with the GST coding sequence. For expression
in the yeast 2-hybrid system, the fragment of PTP-PEST extending
from codon 297 to codon 485 was amplified by PCR using primers that
created EcoRI sites. This fragment was subcloned into pGBT9 (CLON-
TECH, Palo Alto CA) and pGAD424 (CLONTECH) in-frame with the
Gal 4 sequences. Various fragments of paxillin were amplified by PCR
and subcloned in-frame into pGBT9 or pGAD424. The amino-terminal
domain of paxillin (residues 3–332) was subcloned into the pGAD424
vector because expression of this fragment of paxillin in the pGBT9
vector results in autoactivation of the reporter gene.2 The carboxyl-
terminal domain of paxillin (codons 320–559) was subcloned into
pGBT9. Smaller fragments of paxillin, including LIM domains 1, 2, and
3 (codons 320–502), LIM domains 2, 3, and 4 (codons 376–559), LIM
domains 1 and 2 (codons 320–441), LIM domains 2 and 3 (codons
376–502), LIM domains 3 and 4 (codons 436–559), LIM domain 1
(codons 320–381), LIM domain 2 (codons 376–441), LIM domain 3
(codons 436–502), and LIM domain 4 (codons 495–559) were inserted
in-frame into pGAD424. Constructs containing the LIM 4 domain ter-
minate at the stop codon of paxillin. The 39 primers used to amplify each
of the other fragments created an in-frame stop codon. For expression in
mammalian cells, epitope-tagged derivatives of PTP-PEST were engi-
neered into pcDNA 3 as described previously (22). The point mutant
P337A was created by site-directed mutagenesis using the Altered Sites
mutagenesis protocol (Promega, Madison WI). Mutant dl 367–400 was
created by PCR amplification of a DNA fragment encoding residues
99–367 using a primer creating a 39 KpnI site. A second PCR product
containing codons 400–884 was generated using a primer creating a 59
KpnI site. Ligation of the two PCR products via the KpnI sites resulted
in the in-frame fusion of codons 99–367 with codons 400–884. These
fragments were inserted between the HindIII site (at codon 99 of
PTP-PEST) and the SalI site (in the multiple cloning site 39 of the
PTP-PEST termination codon) of pBluescript/PTP-PEST. The mutants
were then subcloned into pcDNA3.
Yeast Protocols—Yeast strain CG-1945 was used for this analysis.
Cells were grown in YPD media, and plasmids were introduced using
the LiAc transformation protocol (26). Transformants were selected on
minimal media plates lacking tryptophan (to select for pGBT9 deriva-
tives), leucine (to select for pGAD424 derivatives), or both (to select for
double transformants). Transformants were purified by streaking on a
selective plate. Expression of the lacZ reporter gene was tested using
the blue/white colony assay. Yeast were streaked onto a 0.45 mM nitro-
cellulose filter (Schleicher and Schuell, Keene NH) on top of a selective
minimal medium plate and grown at 30 °C. The yeast were lysed using
liquid N2, and the nitrocellulose filters were placed on Whatman 3 mM
paper saturated with Z buffer (100 mM sodium phosphate, 10 mM KCl,
1 mM MgSO4) containing 40 mM b-mercaptoethanol and 0.3 mg/ml
5-bromo-4-chloro-3-indolyl-b-D-galactoside. After incubation at room
temperature overnight, colonies were scored as blue or white.
Protein Analysis—Cells were lysed in modified radioimmune precip-
itation buffer (22) or Triton X-100 lysis buffer (22), and the protein
concentration was determined using the bicinchoninic acid assay
(Pierce). Immunoprecipitations were performed using approximately
500 mg of cell lysate and 5 ml of polyclonal antisera or 2 mg of purified
antibody. Monoclonal antibody KT3 was used to recognize tagged vari-
ants of PTP-PEST. Monoclonal antibodies recognizing p130cas and pax-
illin were purchased from Transduction Laboratories (Lexington, KY).
A rabbit polyclonal antiserum recognizing the noncatalytic domain of
PTP-PEST was generated as described below. Immune complexes were
precipitated using protein A-Sepharose beads or goat anti-mouse aga-
rose beads. Immune complexes were washed twice with lysis buffer and
twice with Tris-buffered saline. The samples were boiled in Laemmli
sample buffer and analyzed by SDS-PAGE and Western blotting. Phos-
photyrosine was detected using RC20 (Transduction Laboratories). En-
hanced chemiluminescence was used for detection (Amersham Pharma-
cia Biotech).
Generation of PTP-PEST Polyclonal Antiserum—A GST fusion pro-
tein containing the carboxyl-terminal 304 amino acids of PTP-PEST
was used as antigen to prepare polyvalent rabbit antiserum as de-
scribed previously (27). The fusion protein was purified on glutathione
beads, eluted with 2% SDS and dialyzed against phosphate-buffered
saline. For primary immunizations, 1 mg of fusion protein in phos-
phate-buffered saline was emulsified with complete Freund’s adjuvant
and injected subcutaneously into female New Zealand White rabbits.
For all boosts, 500 mg of antigen in phosphate-buffered saline was
emulsified with Freund’s incomplete adjuvant and injected subcutane-
ously. Serum was prepared by centrifugation of cellular and clotted
material from whole blood.
In Vitro Protein Binding Assays—Fragments of PTP-PEST were
expressed as GST fusion proteins and purified as described (28). Unless
otherwise indicated, 1–2 mg of fusion protein (immobilized to glutathi-
one beads) was incubated with 100–200 mg of lysate for 1 h. The beads
were washed as described for immune complexes above, and bound
paxillin was detected by Western blotting.
RESULTS
PTP-PEST Binds to the LIM Domains of Paxillin—The yeast
two-hybrid system was used to map the PTP-PEST binding site
on paxillin. The carboxyl-terminal half of paxillin was ex-
pressed as a GAL4 DNA binding domain fusion protein using
the pGBT9 vector. A fragment of PTP-PEST containing the
paxillin-binding site (residues 297–485) was expressed as a
GAL4 activation domain fusion protein using the pGAD424
vector. Coexpression of these two proteins induced expression
of the lacZ reporter as assessed using a colorimetric assay (Fig.
1A). When the amino-terminal half of paxillin was expressed
alone as a GAL4 DNA fusion protein, it activated the reporter
gene.2 Therefore reciprocal constructs were engineered to de-
termine whether the amino-terminal domain of paxillin inter-
acted with PTP-PEST. Residues 297–485 of PTP-PEST were
expressed as a GAL4 DNA binding domain fusion protein and
the amino-terminal domain of paxillin was expressed as a
GAL4 activation domain fusion protein. Coexpression of these
two proteins failed to activate expression of the reporter gene
(Fig. 1A). Despite their inability to interact, both of these fusion
proteins were functional in yeast. The amino-terminal domain
of paxillin interacted with a GAL4 DNA binding domain fusion
protein containing the paxillin-binding site of FAK (Fig. 1A).
The GAL4 DNA binding domain/PTP-PEST fusion protein in-
teracted with several GAL4 activation domain/paxillin LIM
domain fusion proteins (see below). Thus in the yeast two-
hybrid system PTP-PEST binds to the carboxyl-terminal, LIM
domain containing half of paxillin.
To validate the findings from the yeast two-hybrid system,
fragments of paxillin were transiently expressed in COS cells
and tested for PTP-PEST binding activity. The amino- and
carboxyl-terminal halves of paxillin were subcloned into
pcDNA3 for transient expression. Each was engineered to con-
tain the KT3 epitope tag at the carboxyl terminus. Both of
these constructs were efficiently expressed in COS cells as
determined by Western blotting whole cell lysates using the
KT3 monoclonal antibody (Fig. 2, lanes 1 and 2). To examine
PTP-PEST binding, cell lysates were incubated with a GST
fusion protein containing PTP-PEST residues 297–494, which2 Unpublished observations.
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was immobilized on glutathione-agarose beads. The beads were
collected and washed, and associated fragments of paxillin
were detected by Western blotting with KT3. The carboxyl-
terminal half of paxillin was found associated with the GST/
PTP-PEST fusion protein (Fig. 2, lane 3). Although the amino-
terminal half of paxillin was expressed in the COS cell lysates,
it failed to associate with the GST/PTP-PEST fusion protein
(Fig. 2, lane 4). These results are in accord with the yeast
two-hybrid data and demonstrate that the PTP-PEST binding
region is within the carboxyl-terminal half of paxillin.
To further refine the PTP-PEST binding site within paxillin,
a series of deletion mutants was engineered and analyzed in
the yeast two-hybrid system for interaction with PTP-PEST.
Originally, the paxillin/PTP-PEST interaction was reconsti-
tuted in yeast by expressing the four paxillin LIM domains as
a GAL4 DNA binding domain fusion protein. Expression of this
construct alone did not activate the reporter gene.2 However,
expression of GAL4 DNA binding domain fusion proteins con-
taining fewer than four LIM domains resulted in activation of
the reporter gene.2 To circumvent this problem, the reciprocal
constructs were built and analyzed. Thus a GAL4 DNA binding
domain/PTP-PEST fusion protein was tested for interaction
with GAL4 activation domain/paxillin LIM domain fusion pro-
teins. Deletion of LIM 4 abrogated interaction with PTP-PEST
(Fig. 1B). In contrast, a fusion protein containing paxillin LIM
domains 2, 3, and 4 did interact with PTP-PEST in the two-
hybrid system (Fig. 1B). Next, fusion proteins containing pairs
of LIM domains from paxillin were analyzed. Whereas a pro-
tein containing LIM domains 3 and 4 from paxillin interacted
with PTP-PEST, fusion proteins containing either LIM do-
mains 1 and 2 or LIM domains 2 and 3 failed to interact (Fig.
1C). Additional constructs containing each of the individual
LIM domains of paxillin fused to the GAL 4 activation domain
were tested but all failed to interact with PTP-PEST in the
two-hybrid system.2 The failure of individual LIM domains to
interact with PTP-PEST could indicate that a functional bind-
ing site is composed of sequences from both LIM 3 and LIM4. In
contrast, the stability of the structure or the strength of the
interaction of individual LIM domains may simply be compro-
mised. To attempt to strengthen the potential interaction be-
tween individual LIM domains and PTP-PEST, multiple copies
of individual LIM domains were engineered in-frame with the
Gal 4 activation domain. However, tandem copies of LIM do-
main 3 (called LIM 33) or LIM domain 4 (called LIM 44) both
failed to interact with PTP-PEST in the yeast 2-hybrid system
(Fig. 1C). The results of this analysis demonstrate that the
PTP-PEST binding site on paxillin lies within LIM domains 3
and 4.
PTP-PEST Contains Separate p130cas and Paxillin Binding
Sites—It was previously demonstrated that a recombinant fu-
sion protein containing PTP-PEST codons 297–494 could di-
rectly bind to both p130cas and paxillin (22). The p130cas bind-
ing site in PTP-PEST has been identified as the proline-rich
sequence extending from amino acid 333 to 338 (21). The rec-
ognition binding sites for several LIM domains have been iden-
tified, and a proline containing sequence has been implicated
as the binding site for one of the LIM domains of enigma (29).
To exclude the possibility that paxillin binds to the same pro-
line rich region as p130cas, two GST fusion proteins containing
PTP-PEST residues 276–400 were utilized. One contained wild
type PTP-PEST sequences and the other contained a point
mutation, proline 337 to alanine, which has been shown to
abrogate association with the p130cas SH3 domain (21). Each
fusion protein was immobilized on glutathione beads, incu-
FIG. 1. Yeast 2-hybrid analysis of paxillin/PTP-PEST interac-
tion. A, yeast containing pGBT9/paxillin carboxyl terminus (Cterm) 1
pGAD424/PTP-PEST, pGBT9/PTP-PEST 1 pGAD424/paxillin amino
terminus (Nterm), or pGBT9/FAK Cterm 1 pGAD424/paxillin Nterm
were grown on nitrocellulose on miminal medium lacking leucine and
tryptophan. The resulting colonies were analyzed using the blue/white
assay. B, yeast containing pGBT9/paxillin Cterm 1 pGAD424/PTP-
PEST, pGBT9/PTP-PEST 1 pGAD424/paxillin LIM 123, or pGBT9/
PTP-PEST 1 pGAD424/paxillin LIM 234 were analyzed as in A. C,
yeast containing pGBT9/PTP-PEST and either pGAD424/paxillin LIM
12, pGAD424/paxillin LIM 23, pGAD424/paxillin LIM 34, pGAD424/
paxillin LIM 33, or pGAD424/paxillin LIM 44 were analyzed as in A.
FIG. 2. The LIM domains of paxillin bind PTP-PEST in vitro.
Cells transfected with constructs designed to express either the epitope-
tagged amino-terminal half of paxillin (lanes 2 and 4) or the tagged
carboxyl-terminal half of paxillin (lanes 1 and 3) were analyzed. Ex-
pression was verified by Western blotting whole cell lysates with KT3
(lanes 1 and 2). Lysates were incubated with GST/PTP-PEST, and
bound fragments of paxillin were detected by Western blotting with
KT3 (lanes 3 and 4).
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bated with cell lysate and associated p130cas and paxillin de-
tected by Western blotting. The wild type PTP-PEST sequences
bound to both paxillin and p130cas (Fig. 3, top and middle
panels, lane 2). The P337A mutant failed to associate with
p130cas (Fig. 3, middle panel, lane 3) but exhibited undimin-
ished paxillin binding activity (Fig. 3, top panel, lane 3). There-
fore, the paxillin-binding site was distinct from the p130cas
binding site.
To further delineate the paxillin-binding site, a series of GST
fusion proteins containing different fragments of PTP-PEST
was engineered and characterized for paxillin binding activity
(Fig. 4). A fusion protein containing PTP-PEST residues 277–
398 bound paxillin as well as fusion proteins containing PEST
residues 297–492 and 297 to the carboxyl terminus of the
protein (Fig. 5A, top panel, lanes 3 and 8, and data not shown).
A series of amino-terminal deletions of the GST/PTP-PEST
277–398 construct was analyzed. Deletion of 61 residues had no
effect upon binding. Thus GST/PTP-PEST 338–390 had undi-
minished paxillin-binding activity (Fig. 5B, top panel, lanes 3
and 4). Deletion of an additional 14 residues compromised
paxillin binding. Although GST/PTP-PEST 352–398 exhibited
binding activity, it bound to paxillin much more weakly than
GST/PTP-PEST 338–390 (Fig. 5B, top panel, lanes 4 and 5).
Further deletion from the amino terminus very severely com-
promised paxillin binding. GST/PTP-PEST 371–492 exhibited
drastically reduced binding activity (Fig. 5A, top panel, lane 5).
In some experiments, a small amount of bound paxillin was
detected, whereas in others, no paxillin was detected. A series
of carboxyl-terminal deletions was also built and analyzed.
Truncation of the carboxyl terminus to residue 390 had little
effect on paxillin binding activity (Fig. 5B, top panel, lane 4).
However, a deletion extending to residue 368 had a severe
effect upon paxillin binding. Thus GST/PTP-PEST 277–368
exhibited very weak binding (Fig. 5A, top panel, lane 7). In
some experiments, paxillin binding was detectable, whereas in
others it was not.
These results suggest that the minimal paxillin-binding site
in PTP-PEST extends from residue 338 through residue 390.
Removal of residues from either the amino or carboxyl termini
of this fragment dramatically reduced, but did not totally ab-
rogate, paxillin-binding activity. This observation could be ex-
plained if further deletion destabilized a single binding site.
Alternatively, this observation could indicate that there are
two weaker paxillin-binding sites within this region of PTP-
PEST, and both binding sites are required for full binding
activity. This idea is consistent with the observations that
GST/PTP-PEST 277–368 and GST/PTP-PEST 371–492 both
exhibit very weak but detectable paxillin binding activity. This
hypothesis was further tested by more extensively analyzing
the binding activity of two nonoverlapping constructs, GST/
PTP-PEST 277–368 and GST/PTP-PEST 371–492. Although
both fusion proteins bound very weakly to paxillin under the
standard conditions of interaction, significant binding activity
was detected if 10-fold more fusion protein was used in the
binding reaction (Fig. 5C, top panel). Importantly, under these
conditions, GST alone did not detectably bind paxillin (Fig. 5C,
top panel, lane 2). Therefore, the interaction is apparently still
specific under these conditions. These results suggest that
there are two sites of PTP-PEST that can weakly interact with
paxillin. One site lies between amino acids 338 and 368 and the
other resides between residues 371 and 390. Both weak binding
sites are required for the efficient association of paxillin with
PTP-PEST.
Generation of a PTP-PEST Polyclonal Antiserum—To fur-
ther characterize PTP-PEST, a polyclonal antiserum recogniz-
ing a fragment of the noncatalytic domain was generated. The
carboxyl-terminal 304 residues of PTP-PEST were expressed
as a GST fusion protein and purified using glutathione-agarose
beads. The fusion protein was used as an antigen to raise
polyvalent antiserum in rabbits. The antiserum was character-
ized using lysates of 293 cells and 293 cells expressing exoge-
nous PTP-PEST. In a Western blot of whole cell lysate, the
antiserum detected proteins of 105 (a doublet), 70, 65, 45, and
35 kDa (Fig. 6A, lane 3). Preimmune serum recognized a major
species of 45 kDa and several lower molecular mass species
(Fig. 6A, lanes 1 and 2). Therefore these proteins were not
specifically recognized by the antiserum in Western blots. The
105-kDa doublet was endogenous PTP-PEST and was recog-
nized by another PTP-PEST antiserum (22).2 In addition to
these bands, lysates from 293 cells expressing exogenous, mu-
rine PTP-PEST exhibited a major 120-kDa species (Fig. 6A,
lane 4). Further, the intensity of the 65-kDa band was elevated.
This 65-kDa species was a PTP-PEST breakdown product be-
cause lysates of 293 cells expressing deletion variants of PTP-
PEST exhibit corresponding increases in the electrophoretic
mobility of this species (Fig. 7A). The antiserum was further
characterized by immunoprecipitation analysis. The antiserum
immunoprecipitated the 105-kDa endogenous PTP-PEST pro-
tein from 293 cell lysates and both the endogenous and exoge-
nous proteins from lysates of 293 cells transiently expressing
PTP-PEST (Fig. 6B, lanes 7 and 8). The 65- and 70-kDa pro-
teins were weakly detected in these immune complexes. Pre-
immune serum failed to precipitate these proteins (Fig. 6B,
lanes 5 and 6). Thus, this antiserum recognized both endoge-
nous and exogenous PTP-PEST by both immunoprecipitation
and Western blotting. The antiserum also recognized an un-
known 65/70-kDa doublet by Western blotting, although these
species were not efficiently immunoprecipitated by the
antiserum.
Expression and Characterization of PTP-PEST Mutants—A
previously described deletion mutant of PTP-PEST lacking
amino acids 297–493 is defective for paxillin binding (22).
Presumably, this mutant is also defective for p130cas binding
because the p130cas SH3 binding site has also been deleted.
FIG. 3. The paxillin binding site of PTP-PEST is distinct from
the p130cas binding site. Lysates from CE cells were incubated with
glutathione beads containing immobilized GST (lane 1), GST/PTP-
PEST 276–400 (lane 2), or GST/PTP-PEST 276–400/P337A (lane 3).
The proteins that bound to the beads were analyzed by Western blotting
for paxillin (top panel) or p130cas (middle panel). The GST fusion pro-
teins were analyzed by SDS-PAGE and staining with Coomassie Blue
(bottom panel). Arrows denote the positions of the molecular mass
markers.
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Two additional mutants were engineered to separate the
p130cas and paxillin binding defects. First, a point mutation
destroying the p130cas binding site (P337A) was created (21).
Second, an additional deletion mutant lacking residues 367–
400 was engineered. Epitope-tagged versions of these mutants
were subcloned into pcDNA 3.1 for expression in mammalian
cells. Wild type PTP-PEST, the P337A point mutant, dl 297–
493, and dl 367–400 were transiently expressed in 293 cells.
Expression of each construct was verified by Western blotting
using a polyclonal PTP-PEST antiserum. Comparable levels of
expression were achieved for each protein (Fig. 7A). Each mu-
tant was tested for its ability to associate with endogenous
p130cas and paxillin by coimmunoprecipitation and Western
blotting. Exogenous PTP-PEST was immunoprecipitated using
the KT3 monoclonal antibody and the immune complexes were
Western blotted for paxillin. Wild type PTP-PEST and the
P337A mutant coimmunoprecipitated paxillin (Fig. 7B, lanes 2
and 5), whereas dl 297–493 and dl 367–400 each exhibited a
dramatic reduction in their ability to associate with paxillin
(Fig. 7B, lanes 3 and 4). Equal amounts of the wild type and
mutant PTP-PEST constructs are recovered by immunoprecipi-
tation with KT3.2 These results are consistent with the in vitro
binding data and verify that the proline-rich p130cas-binding
site is not required for paxillin binding. The association of
p130cas with PTP-PEST was examined by immunoprecipitating
PTP-PEST with a polyclonal antiserum and Western blotting
for p130cas. There was detectable p130cas found in PTP-PEST
immune complexes from lysates of control transfected cells
FIG. 4. GST fusion proteins used in
this analysis. A, a schematic representa-
tion of PTP-PEST is shown. The catalytic
domain lies between residues 55 and 299.
The white ovals depict proline-rich re-
gions found in the carboxyl-terminal non-
catalytic domain of PTP-PEST. B, a sche-
matic illustration of the series of GST/
PTP-PEST fusion proteins used to map
the paxillin binding site. The PTP-PEST
residues contained in each construct are
indicated at the left of each protein. The
paxillin binding activity of each construct
is indicated at the right of the figure.
FIG. 5. Nonoverlapping fragments of PTP-PEST exhibit weak paxillin binding activity. A and B, glutathione beads containing 2 mg of
immobilized GST or GST/PTP-PEST fusion proteins were incubated with 100 mg of CE cell lysate, and bound paxillin was detected by Western
blotting (top panels). Each GST fusion protein was analyzed by SDS-PAGE and staining with Coomassie Blue (bottom panels). GST alone was used
as a negative control (lanes 2, top panels). The residues of PTP-PEST contained in each fusion protein are denoted above each lane. Ten mg of lysate
was included as a loading control (lanes 1, top panels). C, glutathione beads containing GST fusion proteins were incubated with CE cell lysates,
and bound paxillin was detected by Western blotting (top panel). For this analysis, 100 mg of cell lysate was incubated with 25 mg of GST (lane 2),
10 mg of GST/PTP-PEST 277–368 (lane 3), 25 mg of GST/PTP-PEST 277–368 (lane 4), 10 mg of GST/PTP-PEST 371–492 (lane 5), or 25 mg of
GST/PTP-PEST 371–492 (lane 6). Ten mg of lysate was analyzed as a loading control (lane 1). Each fusion protein was analyzed by SDS-PAGE and
staining with Coomassie Blue (bottom panel).
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(Fig. 7C, lane 1). This reflects the coimmunoprecipitation of
p130cas with endogenous, wild type PTP-PEST. The amount of
p130cas recovered by coimmunoprecipitation from lysates of
PTP-PEST expressing cells was increased relative to the
amount seen from control cells. Both wild type PTP-PEST and
dl 367–400 associated with p130cas because elevated levels of
p130cas were detected in PTP-PEST immune complexes (Fig.
7C, lanes 2 and 3). In contrast, the amount of p130cas detected
in PTP-PEST immune complexes from lysates of dl 297–493
expressing cells was equivalent to the amount of p130cas coim-
munoprecipitated from control transfected cells, demonstrating
that dl 297–493 failed to associate with p130cas (Fig. 7C, lane
4). Equivalent amounts of each PTP-PEST construct were re-
covered by immunoprecipitation using the polyclonal antiser-
um.2 Thus, the P337A and dl 367–400 mutants of PTP-PEST
demonstrate the dissociation of p130cas binding activity from
paxillin binding activity in vivo and provide the tools to assess
the role of p130cas and paxillin binding in the biochemical and
biological functions of PTP-PEST.
Biochemical Consequences of PTP-PEST Expression—PTP-
PEST was expressed transiently in 293 cells, and the levels of
cellular phosphotyrosine were examined by Western blotting
whole cell lysates. There was no detectable difference in the
profile of phosphotyrosine containing proteins from control cell
lysates and from lysates of PTP-PEST expressing cells (Fig.
8A). Thus, expression of PTP-PEST did not result in the indis-
criminate dephosphorylation of cellular proteins. Because
p130cas has been implicated as a substrate for PTP-PEST, its
tyrosine phosphorylation was examined by immunoprecipita-
tion and Western blotting. There was detectable phosphoty-
rosine on p130cas in control 293 cells (Fig. 8C, top panel, lane 1).
Expression of PTP-PEST reduced the level of phosphotyrosine
on p130cas (Fig. 8C, top panel, lane 2). After stripping and
reprobing the blot with a p130cas antibody, it was evident that
equal amounts of protein were present in each lane (Fig. 8C,
middle panel). Thus, expression of PTP-PEST results in de-
phosphorylation of p130cas. Paxillin is also a candidate sub-
strate for PTP-PEST because it is an associated phosphoty-
rosine containing protein. Its level of tyrosine phosphorylation
was also examined by immunoprecipitation and Western blot-
ting. Transient expression of PTP-PEST resulted in a reduction
of the phosphotyrosine content of paxillin (Fig. 8B, top panel,
lanes 1 and 2). Stripping and reprobing the membrane with a
paxillin antibody demonstrated that equal amounts of protein
were recovered (Fig. 8B, middle panel). These results suggest
that paxillin may also serve as a PTP-PEST substrate in vivo.
To determine the importance of the noncatalytic domain of
PTP-PEST in targeting these substrates for dephosphoryl-
ation, mutants were analyzed. Two mutants that fail to bind
p130cas, P337A and dl 297–493, were examined. The amount of
phosphotyrosine on p130cas in cells transiently transfected
FIG. 6. Characterization of PTP-
PEST antiserum. A, 25 mg of lysates
from 293 cells (lanes 1 and 3) or 293 cells
expressing exogenous PTP-PEST (lanes 2
and 4) was Western blotted using preim-
mune serum (lanes 1 and 2) or the PTP-
PEST polyclonal antiserum (lanes 3 and
4). The position of the molecular mass
markers are indicated on the left. B, 300
mg of lysate from 293 cells (lanes 1, 3, 5,
and 7) or 293 cells expressing exogenous
PTP-PEST (lanes 2, 4, 6, and 8) was incu-
bated with preimmune serum (lanes 1, 2,
5, and 6) or the PTP-PEST polyclonal an-
tiserum (lanes 3, 4, 7, and 8). The immune
complexes were Western blotted with pre-
immune serum (lanes 1–4) or the poly-
clonal PTP-PEST antiserum (lanes 5–8).
The position of the molecular mass mark-
ers are indicated on the left. The strongly
reactive bands from 40–60 kDa and be-
low 29 kDa are the immunoprecipitating
antibodies that were detected with the
anti-rabbit secondary antibody used in
these experiments.
FIG. 7. Expression and characterization of PTP-PEST mu-
tants. 293 cells were transfected with empty pcDNA (lanes 1) or pcDNA
containing wild type PTP-PEST (lanes 2), dl 367–400 (lanes 3), dl
297–493 (lanes 4), or P337A (lanes 5). Twenty-five mg of cell lysate was
analyzed by Western blotting using a PTP-PEST polyclonal antiserum
(A). B, exogenous PTP-PEST was immunoprecipitated with KT3 and
associated paxillin was detected by Western blotting. C, PTP-PEST was
immunoprecipitated with a polyclonal antiserum and Western blotted
with a p130cas monoclonal antibody.
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with P337A or dl 297–493 was comparable to phosphotyrosine
levels in control cells (Fig. 8C, top panel, lanes 4 and 5). In
contrast, dl 370–400, which retains p130cas binding activity,
reduced tyrosine phosphorylation of p130cas to the same extent
as wild type PTP-PEST (Fig. 8C, top panel, lanes 2 and 3). Two
mutants defective for paxillin binding, dl 297–493 and dl 367–
400, were also analyzed. The phosphotyrosine content of pax-
illin from lysates of cells expressing either of these mutants
was the same as the level seen in control cells (Fig. 8B, top
panel, lanes 3 and 4). P337A expression resulted in a reduction
of the phosphotyrosine content of paxillin similar to that seen
with expression of wild type paxillin (Fig. 8B, top panel, lane 5).
These results demonstrate that the binding site for the SH3
domain of p130cas is required for PTP-PEST-induced dephos-
phorylation of p130cas in vivo and that the paxillin-binding site
of PTP-PEST is necessary for PTP-PEST-induced dephospho-
rylation of paxillin.
DISCUSSION
The data presented in this report demonstrate that the two
carboxyl-terminal LIM domains of paxillin contain a binding
site for PTP-PEST. The paxillin-binding site on PTP-PEST has
been mapped to a 52-residue region near the catalytic domain,
and the evidence suggests that this binding site is composed of
two binding sites of much weaker activity. PTP-PEST mutants
that fail to associate with either paxillin or p130cas or both have
been engineered and characterized. Expression of PTP-PEST
in 293 cells results in dephosphorylation of p130cas and paxil-
lin. The ability of mutants of PTP-PEST to dephosphorylate
p130cas and paxillin correlates with their ability to associate
with these proteins, demonstrating that interactions with
these substrates via the noncatalytic domain is required for
their dephosphorylation in vivo.
Paxillin and its related proteins, hic-5 and leupaxin, contain
four carboxyl-terminal LIM domains and an amino-terminal
domain that contains four LD motifs and multiple tyrosine
residues that may serve as sites of phosphorylation (30–33).
Paxillin and hic-5 are localized to focal adhesions via their LIM
domains, and the primary targeting sequence in paxillin has
been further localized to the LIM 3 domain (34, 35). LIM
domains have been implicated in mediating protein-protein
interactions (29, 36). Presumably, the interaction of an LIM
domain-binding partner tethers paxillin and hic-5 in focal ad-
hesions. PTP-PEST is the first identified binding partner of
paxillin that interacts with its LIM domains.
Recently, PTP-PEST was isolated as a hic-5-interacting pro-
tein using the hic-5 LIM domains as bait in a yeast 2-hybrid
screen (37). The hic-5 binding site of PTP-PEST was localized
to residues 344–427, a result that is consistent with the results
of our experiments mapping the paxillin-binding site of PTP-
PEST. A recent report has also described mapping studies of
the paxillin/PTP-PEST interaction (38). The paxillin-binding
site in this report was narrowed down to PTP-PEST residues
344–397 using GST fusion proteins containing fragments of
PTP-PEST. A smaller fusion protein extending from residues
344–385 failed to bind paxillin. This result is similar to our
observations that carboxyl-terminal truncation to amino acid
368 dramatically impairs the paxillin binding activity of PTP-
PEST. Cote et al. (38) further implicate proline residue 362 of
PTP-PEST in paxillin binding. Mutation of this residue to
alanine eliminated paxillin-binding (38). It was therefore con-
cluded that proline-rich region 2 (residues 355–374) of PTP-
PEST is the paxillin docking site. However, this region alone
appears insufficient for paxillin binding because a GST fusion
protein containing residues 344–385, and thus containing pro-
line-rich region 2, does not associate with paxillin. These ob-
servations are consistent with our finding that paxillin binds
weakly to two nonoverlapping fragments of PTP-PEST, one of
which contains proline-rich region 2 (and the critical residue
proline 362) and the other of which lies to the carboxyl-termi-
nal side of proline-rich region 2.
The site of PTP-PEST binding on hic-5 has also been mapped
and does not precisely correspond to the site of interaction we
have identified on paxillin (37). The binding site on paxillin has
been narrowed to LIM domains 3 and 4, which is in agreement
with the results of Cote et al. (38). The PTP-PEST binding site
on hic-5 has been further localized to LIM 3 (37). Two lines of
evidence that the hic-5 LIM 3 domain interacts with PTP-PEST
have been presented. First, two overlapping fragments of hic-5
interact with PTP-PEST and the region of overlap is the LIM 3
domain (37). Second, mutation of two residues critical for metal
coordination in the LIM 3 domain, which disrupts the structure
of LIM domains and undoubtedly has dire consequences for the
structural integrity of the protein, ablates PTP-PEST binding
activity in vitro (37). There is no additional direct evidence that
LIM 3 interacts with PTP-PEST because the individual LIM
domain does not associate with PTP-PEST (37), a result that is
in accord with our findings with paxillin. In contrast to the
published hic-5 data, we have failed to detect an interaction
between PTP-PEST and paxillin constructs containing LIM
domains 1, 2, and 3 or LIM domains 2 and 3. It is unlikely that
paxillin and hic-5 interact with PTP-PEST via different se-
quences given the conserved nature of the paxillin and hic-5
sequences. Most likely, these different results reflect subtle
differences in the constructs or the methods of assessing inter-
action. Because perturbation of the structure of LIM domain 3
of hic-5 does not disrupt PTP-PEST binding in vivo, additional
sequences may be required for the interaction (37). Based
upon our analysis of the PTP-PEST/paxillin interaction,
we speculate that these additional sequences may reside
FIG. 8. PTP-PEST-induced dephosphorylation of p130cas and
paxillin. 293 cells were transfected with empty pcDNA (lanes 1) or
pcDNA containing wild type PTP-PEST (lanes 2), dl 367–400 (lanes 3),
dl 297–493 (lanes 4), or P337A (lanes 5). Twenty-five mg of cell lysate
was analyzed by Western blotting using a phosphotyrosine antibody (A)
or with a PTP-PEST polyclonal antiserum (bottom panels of B and C).
B, paxillin was immunoprecipitated, and its phosphotyrosine content
examined by Western blotting (top panel). The blot was stripped and
reprobed with a paxillin monoclonal antibody (middle panel). C, p130cas
was immunoprecipitated, and its phosphotyrosine content was exam-
ined by Western blotting (top panel). The blot was stripped and rep-
robed with a p130cas monoclonal antibody (middle panel).
PTP-PEST Dephosphorylates Paxillin 1411
in LIM domain 4.
PTP-PEST is the first identified protein that interacts with
the LIM domains of paxillin/hic-5. Although PTP-PEST binds
near the focal adhesion targeting sequence of paxillin/hic-5, it
is unlikely to function in directing these proteins to focal ad-
hesions. First, based upon the recoveries of paxillin in PTP-
PEST immune complexes and PTP-PEST in paxillin immune
complexes, there appears to be much more paxillin than PTP-
PEST in the cell (22). Second, a hic-5 mutant that disrupts the
LIM 3 domain is still able to bind PTP-PEST, although the
hic-5 mutant fails to target to focal adhesions (37). Third, hic-5
has been expressed in PTP-PEST2/2 cells and correctly targets
to focal adhesions in the absence of PTP-PEST. Alternatively,
association with paxillin and hic-5 may direct PTP-PEST to
focal adhesions. However, PTP-PEST has never been detected
in focal adhesions. The distribution of exogenously expressed
PTP-PEST in COS cells has been examined by immunofluores-
cence and found to be cytoplasmic, although plating on fi-
bronectin induces a translocation of a fraction of the protein to
the cell periphery (24, 39). A similar, diffuse cellular distribu-
tion of both endogenous and exogenously expressed PTP-PEST
has been observed in subconfluent CE cells.2 Furthermore,
microinjected GST/PTP-PEST fusion proteins containing the
paxillin-binding site do not target to focal adhesions.2 It is
possible that under the appropriate conditions, PTP-PEST may
be found in focal adhesions; however, it is also possible that
PTP-PEST does not localize to or function in focal adhesions.
This might be the case if the association of paxillin with PTP-
PEST and with the binding partner that anchors paxillin in
focal adhesions is mutually exclusive. Given this scenario,
PTP-PEST may associate with a fraction of paxillin that is not
present in focal adhesions. It may function in dephosphoryl-
ation when paxillin is released from focal adhesions. Alterna-
tively, PTP-PEST may function to regulate tyrosine phospho-
rylation in signaling pathways distinct from focal adhesion
signaling.
Given that paxillin directly associates with PTP-PEST (22),
we hypothesized that paxillin may be a PTP-PEST substrate.
Using GST/PTP-PEST catalytic domain fusion proteins, exper-
iments were performed to determine whether paxillin could be
substrate-trapped. Although p130cas was effectively trapped
using this assay, as described previously (20, 40), paxillin could
not be substrate-trapped by inactive PTP-PEST catalytic do-
mains.2 This result is similar to published observations (38).
This assay is very useful for detecting high affinity interactions
between the catalytic site and substrates. However, paxillin
could still function as a PTP-PEST substrate, because a high
affinity interaction with the catalytic domain may not be nec-
essary to facilitate paxillin dephosphorylation given that the
two proteins can directly interact via another interaction. To
further pursue this hypothesis, PTP-PEST was expressed in
293 cells, and tyrosine phosphorylation of paxillin was exam-
ined. In support of the hypothesis that paxillin is a PTP-PEST
substrate, its phosphotyrosine content was reduced upon ex-
pression of PTP-PEST. This result did not appear to be a
consequence of global dephosphorylation of cellular proteins,
because there were no dramatic changes in tyrosine phospho-
rylation of whole cell lysates. In fact, there were no detectable
differences in tyrosine phosphorylation of cellular proteins in
the molecular weight ranges of paxillin and p130cas, despite the
fact that expression of PTP-PEST clearly resulted in reduced
phosphorylation of these proteins. Presumably, other phospho-
tyrosine-containing proteins of similar molecular weight,
which are not PTP-PEST substrates, obscure the reduction in
tyrosine phosphorylation of paxillin and p130cas at the level of
whole cell lysate. Mutants that are defective for paxillin bind-
ing failed to induce its tyrosine dephosphorylation. These mu-
tants still exhibited catalytic activity in “in-gel” PTP assays
and in immune complex PTP assays.2 Further, the paxillin
binding mutants still induce dephosphorylation of p130cas in
293 cells. These results suggest that paxillin may truly be a
PTP-PEST substrate in vivo. This result is in contrast to an-
other report that PTP-PEST overexpression reduces tyrosine
phosphorylation of p130cas but has no effect upon tyrosine
phosphorylation of paxillin (23). It is difficult to compare our
findings with these because different cell types and modes of
expression were used in the two studies. In agreement with our
observation that paxillin may be a PTP-PEST substrate, PTP-
PEST2/2 fibroblasts exhibit elevated levels of tyrosine phos-
phorylation of paxillin, which is the expected consequence of
removing the enzyme that functions to dephosphorylate paxil-
lin (24). Although further experimentation will be required to
rigorously determine whether paxillin is a PTP-PEST sub-
strate, our data and the data from the PTP-PEST2/2 fibro-
blasts clearly support the candidacy of paxillin as a substrate.
p130cas has emerged as the prototypical substrate for PTP-
PEST. It can be substrate-trapped by catalytically defective
PTP-PEST mutants, and its phosphotyrosine content is re-
duced upon overexpression of PTP-PEST and is elevated in
PTP-PEST2/2 cells (20, 23, 24, 40). p130cas also associates with
the noncatalytic domain of PTP-PEST via an SH3 domain
mediated interaction and this interaction is required for the
dephosphorylation of p130cas by recombinant PTP-PEST in cell
lysates (21). We have extended this observation and demon-
strated that the interaction between p130cas and the noncata-
lytic domain of PTP-PEST is necessary for its dephosphoryl-
ation in vivo. Thus, despite the high affinity interaction
between the catalytic domain of PTP-PEST and tyrosine-phos-
phorylated p130cas, it is the interaction with the noncatalytic
domain of PTP-PEST that directs p130cas dephosphorylation.
We suggest that paxillin is a second class of PTP-PEST sub-
strate. Although it does not exhibit high affinity binding to the
catalytic domain of PTP-PEST in vitro, tyrosine phosphoryla-
tion of paxillin can be regulated by PTP-PEST in vivo. As with
p130cas, interactions with the noncatalytic domain of PTP-
PEST direct the dephosphorylation of paxillin in vivo. Thus,
the recurring theme is that the noncatalytic domain of PTP-
PEST contains binding sites that recruit tyrosine-phosphory-
lated substrates for dephosphorylation.
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